Priyanka Sharma

Has grant

Associate Professor

University of Kansas Medical Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Support of SWOG Related Breast Cancer Research

Open Date: 2023-10-01

Close Date: 2024-09-30

Grant: Close

Support of SWOG Related Breast Cancer Research

Open Date: 2022-10-01

Close Date: 2023-09-30

Grant: Close

Support of SWOG Related Breast Cancer Research

Open Date: 2021-10-01

Close Date: 2022-09-30

Grant: Close

Support of SWOG Related Breast Cancer Research

Open Date: 2021-10-01

Close Date: 2022-09-30

Articles (6)

Purpose: CD4 T-cell immunity is associated with improved survival in patients with breast cancer. We previously reported a phase I trial evaluating a folate receptor alpha (FRα) vaccine administered with cyclophosphamide (CP), demonstrating excellent safety and immunogenicity. To simplify the vaccine strategy for ease of use, we report here the results of a randomized phase II trial evaluating a lower vaccine dose alongside the original dose, administered with or without CP pretreatment. Patients and Methods: Patients with triple-negative breast cancer who completed all systemic and local therapies were assigned to receive either low-dose (825 μg) or high-dose (2.5 mg) vaccine peptides plus GM-CSF in six 4-week cycles, with or without CP prior to vaccination. Safety was monitored, and immunogenicity was evaluated before and after vaccination. Results: A total of 80 patients were dosed with vaccine, and 58 patients were evaluable for immunogenicity. Vaccination was well tolerated and elicited immunity in 83% of patients. Levels of FRα-specific T cells were high, persistent, and comparable with T-cell levels against tetanus toxoid. No differences in immunity were observed between the two doses. CP pretreatment also did not affect the immune responses. Recurrences occurred in eight evaluable patients and were unrelated to the treatment arm. No patients died during the study because of their disease. Conclusions: The reduced-dose FRα vaccine is as effective as the original dose and does not require CP to generate maximal immunity. These findings may inform the design of trials testing efficacy in triple-negative breast cancer or other cancers.

Year:

2026

Purpose: Circulating tumor cells (CTC) are biomarkers associated with poor prognosis and treatment resistance in hormone receptor–positive (HR+)/HER2-negative metastatic breast cancer (MBC). This analysis evaluates the prognostic role of baseline CTC enumeration and its interaction with treatment regimens in patients progressing on CDK4/6 inhibitors. Experimental Design: The PACE trial is a phase II, multicenter, randomized study of patients with HR+/HER2− MBC experiencing progression on aromatase inhibitors and CDK4/6 inhibitors. Patients were randomized 1:2:1 to receive fulvestrant (F), F + palbociclib (F + P), or F + P + avelumab (F + P + A). Baseline CTCs were enumerated using CellSearch with a threshold of ≥5 CTCs/7.5 mL to classify patients as stage IV indolent or stage IV aggressive . Concurrent ctDNA analysis was performed using Guardant360. Progression-free survival (PFS) was the primary endpoint. Results: Among 220 randomly assigned patients, 203 were evaluable for baseline CTCs; 76% had detectable CTCs and 49% were stage IV aggressive . Patients with de novo MBC were more frequently stage IV aggressive (47.5% vs. 30.8%). Baseline CTCs were prognostic with median PFS of 5.7 months for stage IV indolent and 3.5 months for stage IV aggressive patients [HR = 1.69; 90% confidence interval (CI), 1.27–2.24; P aggressive patients, F + P and F + P + A improved PFS versus fulvestrant alone (HR = 0.43; 90% CI, 0.25–0.71 and HR = 0.26; 90% CI, 0.14–0.49, respectively). No benefit was observed in stage IV indolent patients (interaction P = 0.0148 and P = 0.0033, respectively). Conclusions: Baseline CTC enumeration provides significant prognostic information in HR+/HER2− MBC. Stage IV aggressive patients derive greater benefit from F + P or F + P + A over fulvestrant alone, independent of clinical or ctDNA features. This highlights the potential of CTCs to guide treatment decision-making.

Year:

2025

Multivariable Cox regression in terms of PFS. CTCs enumeration was corrected for ESR1, PIK3CA, RB1 mutational status and clinically relevant features (i.e., visceral involvement, duration of prior CDK4/6 inhibitor, endocrine sensitivity, therapy between prior CDK4/6i and randomization).

Year:

2025

PACE Trial Schema. Total planned enrollment was 220 patients. Primary objective: superiority of fulvestrant+palbociclib vs fulvestrant alone (A). Secondary objective: superiority fulvestrant+palbociclib+avelumab vs fulvestrant alone (B).

Year:

2025

Purpose: Stromal tumor-infiltrating lymphocytes (sTIL) are associated with pathologic complete response (pCR) and long-term outcomes for triple-negative breast cancer (TNBC) in the setting of anthracycline-based chemotherapy. The impact of sTILs on refining outcomes beyond prognostic information provided by pCR in anthracycline-free neoadjuvant chemotherapy (NAC) is not known. Experimental Design: This is a pooled analysis of two studies where patients with stage I (T>1 cm)–III TNBC received carboplatin (AUC 6) plus docetaxel (75 mg/m 2 ; CbD) NAC. sTILs were evaluated centrally on pre-treatment hematoxylin and eosin slides using standard criteria. Cox regression analysis was used to examine the effect of variables on event-free survival (EFS) and overall survival (OS). Results: Among 474 patients, 44% had node-positive disease. Median sTILs were 5% (range, 1%–95%), and 32% of patients had ≥30% sTILs. pCR rate was 51%. On multivariable analysis, T stage (OR, 2.08; P = 0.007), nodal status (OR, 1.64; P = 0.035), and sTILs (OR, 1.10; P = 0.011) were associated with pCR. On multivariate analysis, nodal status (HR, 0.46; P = 0.008), pCR (HR, 0.20; P P = 0.049) were associated with OS. At 30% cut-point, sTILs stratified outcomes in stage III disease, with 5-year OS 86% versus 57% in ≥30% versus P = 0.014), and numeric trend in stage II, with 5-year OS 93% versus 89% in ≥30% versus P = 0.179). Among stage II–III patients with pCR, EFS was better in those with ≥30% sTILs (HR, 0.16; P , 0.047). Conclusions: sTILs density was an independent predictor of OS beyond clinicopathologic features and pathologic response in patients with TNBC treated with anthracycline-free CbD chemotherapy. Notably, sTILs density stratified outcomes beyond tumor–node–metastasis (TNM) stage and pathologic response. These findings highlight the role of sTILs in patient selection and stratification for neo/adjuvant escalation and de-escalation strategies.

Year:

2024

Purpose: Stromal tumor-infiltrating lymphocytes (sTIL) are associated with pathologic complete response (pCR) and long-term outcomes for triple-negative breast cancer (TNBC) in the setting of anthracycline-based chemotherapy. The impact of sTILs on refining outcomes beyond prognostic information provided by pCR in anthracycline-free neoadjuvant chemotherapy (NAC) is not known. Experimental Design: This is a pooled analysis of two studies where patients with stage I (T>1 cm)–III TNBC received carboplatin (AUC 6) plus docetaxel (75 mg/m 2 ; CbD) NAC. sTILs were evaluated centrally on pre-treatment hematoxylin and eosin slides using standard criteria. Cox regression analysis was used to examine the effect of variables on event-free survival (EFS) and overall survival (OS). Results: Among 474 patients, 44% had node-positive disease. Median sTILs were 5% (range, 1%–95%), and 32% of patients had ≥30% sTILs. pCR rate was 51%. On multivariable analysis, T stage (OR, 2.08; P = 0.007), nodal status (OR, 1.64; P = 0.035), and sTILs (OR, 1.10; P = 0.011) were associated with pCR. On multivariate analysis, nodal status (HR, 0.46; P = 0.008), pCR (HR, 0.20; P P = 0.049) were associated with OS. At 30% cut-point, sTILs stratified outcomes in stage III disease, with 5-year OS 86% versus 57% in ≥30% versus P = 0.014), and numeric trend in stage II, with 5-year OS 93% versus 89% in ≥30% versus P = 0.179). Among stage II–III patients with pCR, EFS was better in those with ≥30% sTILs (HR, 0.16; P , 0.047). Conclusions: sTILs density was an independent predictor of OS beyond clinicopathologic features and pathologic response in patients with TNBC treated with anthracycline-free CbD chemotherapy. Notably, sTILs density stratified outcomes beyond tumor–node–metastasis (TNM) stage and pathologic response. These findings highlight the role of sTILs in patient selection and stratification for neo/adjuvant escalation and de-escalation strategies.

Year:

2024

Collaborators (24)

Stephanie L. Graff

Brown University

UNITED STATES
View details

Carolina Reduzzi

Assistant Professor

Weill Cornell Medicine

UNITED STATES
View details

Keith Knutson

Mayo Clinic Florida

UNITED STATES
View details

Coralia Bueno Muiño

-

SPAIN
View details

Angela DeMichele

University of Pennsylvania

UNITED STATES
View details

Richard Kenney

Chief Medical Officer

-

UNITED STATES
View details

Cynthia X. Ma

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Nadine Norton

Associate Professor

Mayo Clinic Florida

UNITED STATES
View details

Yara G Abdou

University of North Carolina at Chapel Hill

UNITED STATES
View details

Qamar Khan

Professor

The University of Kansas Health System

UNITED STATES
View details

Sara Lopez-Tarruella

ASSOCIATE PROFESSOR

Universidad Complutense de Madrid

SPAIN
View details

Joseph A. Sparano

Chief, Division of Hematology/Oncology; Deputy Director, Tisch Cancer Institute

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Harold Burstein

Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Rachel Yoder

University of Kansas Medical Center

UNITED STATES
View details

Sonya Reid

Vanderbilt University Medical Center

UNITED STATES
View details

Aziza Nassar

Consultant/Professor of Pathology

Medical University of South Carolina

UNITED STATES
View details

Shane Stecklein

University of Kansas Cancer Center

UNITED STATES
View details

Rubina Qamar

Associate Professor

University of Wisconsin-Madison Carbone Cancer Center

UNITED STATES
View details

Kathy Miller

Indiana University Bloomington

UNITED STATES
View details

Andrew K. Godwin

University of Kansas Medical Center

UNITED STATES
View details

Erica Mayer

Dana-Farber Cancer Institute

UNITED STATES
View details

Massimo Cristofanilli

Professor of Medicine

Weill Cornell Medicine

UNITED STATES
View details

Miguel Martin

Universidad Complutense de Madrid

SPAIN
View details

Reshma Mahtani

Chief of Breast Medical Oncology

Sylvester Comprehensive Cancer Center, University of Miami

UNITED STATES
View details